Search

everythinglearnresearchcommunity

for

Search:↓

NKIRAS2 can suppress certain skin tumors but its effect on cancer varies with context and expression level.

GI198745 is more potent and longer-lasting than finasteride, potentially better for treating hair loss.

QLT0267 stops hair follicle cell growth and movement.

ACKR2 helps prevent skin scarring and hair loss by controlling inflammation.

DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.

Epristeride's metabolism involves key metabolites and proteins, affecting its use in doping tests.

Certain drugs that block specific enzymes can help treat prostate diseases.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.

Changing the C-ring structure in certain compounds can make them better at blocking a specific human enzyme.

Promising cancer treatments were found, but the manufacturer closed.

5αR inhibitors help slow early prostate cancer cell growth, suggesting combined treatments are needed.

TAK-279 effectively reduces psoriasis symptoms and is safe.

Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.

Finasteride helps female-pattern hair loss.

ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.

JAK inhibitors show promise for treating various skin disorders effectively and safely.

LY320236 is a strong blocker of two enzymes that change testosterone into dihydrotestosterone and might help treat conditions related to male hormones.

A new compound may effectively inhibit the enzyme linked to BPH and hair loss.

Blocking mTORC1 reduces skin tumor growth in mice.

Isoginkgetin reduces inflammation in cells by blocking NF-κB activation.

EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

ITK inhibitors may effectively treat alopecia areata.

A patient with advanced kidney cancer and no hepatitis C developed skin inflammation due to a drug called interferon alpha-2a.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

PRIDE syndrome helps identify skin side effects from EGFR inhibitors like erlotinib.

Afatinib, neratinib, and zanubrutinib could be effective against KRASG12C-mutant tumors.